|
DE10109897A1
(en)
*
|
2001-02-21 |
2002-11-07 |
Novosom Ag |
Optional cationic liposomes and their use
|
|
DE10207177A1
(en)
*
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Optionally cationic lipids
|
|
US7858117B2
(en)
*
|
2002-02-21 |
2010-12-28 |
Novosom Ag |
Amphoteric liposomes and their use
|
|
CA2487274A1
(en)
*
|
2002-05-06 |
2003-11-13 |
Nucleonics Inc. |
Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
|
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
|
DE10255106A1
(en)
*
|
2002-11-24 |
2004-06-09 |
Novosom Ag |
Liposomal glucocorticoids
|
|
EP1547580A1
(en)
*
|
2003-12-23 |
2005-06-29 |
MediGene Oncology GmbH |
Loading of a camptothecin drug into colloidal nanoparticles
|
|
DE102004054730A1
(en)
|
2004-03-28 |
2006-05-11 |
Novosom Ag |
Serum stable amphoteric liposomes
|
|
US8815599B2
(en)
*
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
|
JP2008518998A
(en)
*
|
2004-11-05 |
2008-06-05 |
ノヴォソム アクチェンゲゼルシャフト |
Improvements in or relating to pharmaceutical compositions comprising oligonucleotides as active substances
|
|
EP1764090A1
(en)
*
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Amphoteric liposomes for local drug applications
|
|
AU2005306075A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Novosom Ag |
Improvements in or relating to pharmaceutical compositions for local administration
|
|
EP1676569A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Pevion Biotech Ltd. |
Lyophilization of virosomes
|
|
CA2889540A1
(en)
*
|
2005-09-15 |
2007-03-22 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
|
EP1911443A1
(en)
*
|
2006-10-13 |
2008-04-16 |
Novosom AG |
Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
|
|
US20080088046A1
(en)
*
|
2006-10-13 |
2008-04-17 |
Steffen Panzner |
Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
|
|
US20120021042A1
(en)
*
|
2005-09-15 |
2012-01-26 |
Steffen Panzner |
Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
|
|
EP1764089A1
(en)
*
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serum stable liposomes comprising amphoter II lipid mixtures
|
|
WO2007043049A1
(en)
*
|
2005-10-11 |
2007-04-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compositions for silencing the expression of vdac1 and uses thereof
|
|
ES2548240T3
(en)
|
2005-12-01 |
2015-10-15 |
Pronai Therapeutics, Inc. |
Therapies for cancer and pharmaceutical compositions used therein
|
|
ES2419106T3
(en)
*
|
2005-12-01 |
2013-08-19 |
Pronai Therapeutics, Inc. |
Amphoteric liposome formulation
|
|
ES2594368T3
(en)
|
2005-12-08 |
2016-12-19 |
Insmed Incorporated |
Lipid-based compositions of anti-infectives to treat lung infections
|
|
EP3354260B1
(en)
*
|
2006-04-06 |
2020-12-09 |
Insmed Incorporated |
Methods for coacervation induced liposomal encapsulation and formulations thereof
|
|
US20140178462A1
(en)
*
|
2006-10-13 |
2014-06-26 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising neutral lipids
|
|
WO2008043575A2
(en)
*
|
2006-10-13 |
2008-04-17 |
Novosom Ag |
Improvements in or relating to amphoteric liposomes
|
|
JP2010513354A
(en)
*
|
2006-12-19 |
2010-04-30 |
ノヴォソム アクチェンゲゼルシャフト |
Lipids and lipid aggregates containing transfection enhancer elements
|
|
PT2308514E
(en)
|
2007-03-23 |
2013-09-06 |
To Bbb Holding B V |
Conjugates for targeted drug delivery across the blood-brain barrier
|
|
US20080260895A1
(en)
*
|
2007-04-17 |
2008-10-23 |
Vermeire Drew A |
Milk replacer composition and product and method for producing the same
|
|
CA2686735A1
(en)
|
2007-05-04 |
2008-11-13 |
Mdrna, Inc. |
Amino acid lipids and uses thereof
|
|
US20100196455A1
(en)
|
2007-05-04 |
2010-08-05 |
Transave, Inc. |
Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
|
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
US8822409B2
(en)
|
2007-06-20 |
2014-09-02 |
Phylogica Limited |
Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
|
|
DE102007029471A1
(en)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
New optional cationic sterols
|
|
EP2200586B1
(en)
*
|
2007-09-07 |
2019-11-13 |
Synvolux IP B.V. |
Improved liposomes and uses thereof
|
|
EP2211840B1
(en)
*
|
2007-10-12 |
2019-12-04 |
Novosom Verwaltungs GmbH |
Amphoteric liposomes comprising neutral lipids
|
|
WO2009149418A2
(en)
*
|
2008-06-06 |
2009-12-10 |
Asuragen, Inc. |
Novel compositions for the in vivo delivery of rnai agents
|
|
US20100112042A1
(en)
|
2008-10-16 |
2010-05-06 |
Mdrna, Inc. |
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
|
|
US20120107389A1
(en)
*
|
2009-03-31 |
2012-05-03 |
Jayanta Bhattacharyya |
Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference
|
|
JP5392707B2
(en)
*
|
2009-03-31 |
2014-01-22 |
株式会社Ｎｔｔドコモ |
Membrane vesicle division system
|
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
|
JP5851399B2
(en)
|
2009-07-09 |
2016-02-03 |
マリーナ バイオテック，インコーポレイテッド |
Amphoteric liposomes containing iminolipids
|
|
ES2386855T3
(en)
*
|
2009-07-09 |
2012-09-03 |
Marina Biotech, Inc. |
Emulation of lipoprotein structures
|
|
ME03327B
(en)
|
2009-12-01 |
2019-10-20 |
Translate Bio Inc |
Steroid derivative for the delivery of mrna in human genetic diseases
|
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3590949B1
(en)
|
2010-10-01 |
2022-05-18 |
ModernaTX, Inc. |
Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US9880151B2
(en)
|
2011-05-23 |
2018-01-30 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
|
CN103906527B
(en)
|
2011-06-08 |
2020-07-10 |
川斯勒佰尔公司 |
Lipid Nanoparticle Compositions and Methods for mRNA Delivery
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RS62993B1
(en)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
CN102532259A
(en)
*
|
2012-03-09 |
2012-07-04 |
中国药科大学 |
Oligopeptide-based cationic lipid derivative and application thereof in pharmaceutical preparation
|
|
CN102603866B
(en)
*
|
2012-03-15 |
2014-01-15 |
中国药科大学 |
Oligopeptide-based pH-sensitive zwitterions and their applications in pharmaceuticals
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
JP2015513912A
(en)
|
2012-04-02 |
2015-05-18 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US20150272880A1
(en)
|
2012-05-21 |
2015-10-01 |
Insmed Incorporated |
Systems for treating pulmonary infections
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
WO2013186793A1
(en)
*
|
2012-06-11 |
2013-12-19 |
Council Of Scientific & Industrial Research |
Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
|
|
AU2013340414B2
(en)
|
2012-10-23 |
2019-05-02 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
CN104884637A
(en)
|
2012-11-05 |
2015-09-02 |
普隆奈治疗公司 |
Methods of using biomarkers for the treatment of cancer by modulation of BCL2 expression
|
|
PL2922554T3
(en)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Terminally modified rna
|
|
ES2743039T3
(en)
|
2012-11-29 |
2020-02-18 |
Insmed Inc |
Vancomycin stabilized formulations
|
|
US9939443B2
(en)
|
2012-12-19 |
2018-04-10 |
Caris Life Sciences Switzerland Holdings Gmbh |
Compositions and methods for aptamer screening
|
|
HUE042640T2
(en)
|
2013-03-14 |
2019-07-29 |
Translate Bio Inc |
CFTR mRNA preparations and related methods and applications
|
|
CN105051190A
(en)
|
2013-03-14 |
2015-11-11 |
夏尔人类遗传性治疗公司 |
Methods for purification of messenger RNA
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
MX2015013177A
(en)
|
2013-03-15 |
2016-10-03 |
Mirna Therapeutics Inc |
Combination cancer treatments utilizing micrornas and egfr-tki inhibitors.
|
|
US20140378528A1
(en)
|
2013-06-24 |
2014-12-25 |
Mirna |
Biomarkers of mir-34 activity
|
|
JP5914418B2
(en)
|
2013-06-26 |
2016-05-11 |
富士フイルム株式会社 |
Lipid particle, nucleic acid delivery carrier, composition for producing nucleic acid delivery carrier, lipid particle production method and gene introduction method
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
CN105980401A
(en)
|
2013-10-03 |
2016-09-28 |
现代治疗公司 |
Polynucleotides encoding low density lipoprotein receptor
|
|
CA2928188A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for argininosuccinate synthetase deficiency
|
|
EA201992208A1
(en)
|
2013-10-22 |
2020-07-31 |
Транслейт Био, Инк. |
TREATMENT OF PHENYLKETONURIA USING mRNA
|
|
WO2015153757A1
(en)
|
2014-04-01 |
2015-10-08 |
Mirna Therapeutics, Inc. |
Microrna dosing regimens
|
|
SG11201608798YA
(en)
|
2014-04-23 |
2016-11-29 |
Modernatx Inc |
Nucleic acid vaccines
|
|
JP6571679B2
(en)
|
2014-04-25 |
2019-09-04 |
トランスレイト バイオ， インコーポレイテッド |
Method for purifying messenger RNA
|
|
PT3142643T
(en)
|
2014-05-15 |
2019-10-28 |
Insmed Inc |
Methods for treating pulmonary non-tuberculous mycobacterial infections
|
|
JP6240570B2
(en)
|
2014-07-17 |
2017-11-29 |
富士フイルム株式会社 |
Lipid particles and nucleic acid delivery carriers
|
|
US10722599B2
(en)
|
2015-02-04 |
2020-07-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
JP7114465B2
(en)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
Compounds and compositions for intracellular delivery of drugs
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MX2019010155A
(en)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Novel codon-optimized cftr mrna.
|
|
JP7332478B2
(en)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
Lipid nanoparticle formulation
|
|
EP3596042B1
(en)
|
2017-03-15 |
2022-01-12 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
SMT202300097T1
(en)
|
2017-03-15 |
2023-05-12 |
Modernatx Inc |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
US11173190B2
(en)
|
2017-05-16 |
2021-11-16 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
Rna formulations
|
|
US11744801B2
(en)
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019045097A1
(en)
*
|
2017-09-04 |
2019-03-07 |
一丸ファルコス株式会社 |
Ph-sensitive liposomes and method for producing same
|
|
EP3679140B1
(en)
|
2017-09-08 |
2022-11-16 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
WO2019077053A1
(en)
*
|
2017-10-20 |
2019-04-25 |
Biontech Rna Pharmaceuticals Gmbh |
Preparation and storage of liposomal rna formulations suitable for therapy
|
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
|
US11571386B2
(en)
|
2018-03-30 |
2023-02-07 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
KR20210024451A
(en)
|
2018-05-02 |
2021-03-05 |
인스메드 인코포레이티드 |
Method for preparing liposomal drug formulation
|
|
US20190381034A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Ming Fang |
Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
|
|
EP3841208A1
(en)
|
2018-08-24 |
2021-06-30 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
EP3843845A4
(en)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH'S DISEASE
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
CN112996854B
(en)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
High-purity PEG lipids and their uses
|
|
EP3852728B1
(en)
|
2018-09-20 |
2024-09-18 |
ModernaTX, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
WO2020106946A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
BR112022004759A2
(en)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Branched tail lipid compositions and compounds for intracellular delivery of therapeutic agents
|
|
EP4133072A4
(en)
|
2020-04-09 |
2024-11-06 |
Verve Therapeutics, Inc. |
CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9
|
|
WO2021255262A1
(en)
|
2020-06-19 |
2021-12-23 |
Sylentis Sau |
siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
|
|
WO2022060871A1
(en)
|
2020-09-15 |
2022-03-24 |
Verve Therapeutics, Inc. |
Lipid formulations for gene editing
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
EP4015634A1
(en)
|
2020-12-15 |
2022-06-22 |
Sylentis, S.A.U. |
Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
TW202305133A
(en)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna compositions and methods of use
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
TW202440929A
(en)
|
2022-12-14 |
2024-10-16 |
加拿大商普羅維登斯治療控股公司 |
Compositions and methods for infectious diseases
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
IL321425A
(en)
|
2022-12-23 |
2025-08-01 |
Biontech Delivery Tech Gmbh |
Composition
|
|
WO2025046121A1
(en)
|
2023-09-01 |
2025-03-06 |
Novoarc Gmbh |
Lipid nanoparticle with nucleic acid cargo and ionizable lipid
|
|
WO2025136963A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Coty Inc. |
Cationic micro-vesicles and functionalized exosome-like vectors for the delivery of functional agent to the skin
|